Literature DB >> 20616783

Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.

Farid Rahimi1, Gal Bitan.   

Abstract

Alzheimer's disease (AD) is a progressive, age-dependent, neurodegenerative disorder with an insidious course that renders its presymptomatic diagnosis difficult(1). Definite AD diagnosis is achieved only postmortem, thus establishing presymptomatic, early diagnosis of AD is crucial for developing and administering effective therapies(2,3). Amyloid beta-protein (Abeta) is central to AD pathogenesis. Soluble, oligomeric Abeta assemblies are believed to affect neurotoxicity underlying synaptic dysfunction and neuron loss in AD(4,5). Various forms of soluble Abeta assemblies have been described, however, their interrelationships and relevance to AD etiology and pathogenesis are complex and not well understood(6). Specific molecular recognition tools may unravel the relationships amongst Abeta assemblies and facilitate detection and characterization of these assemblies early in the disease course before symptoms emerge. Molecular recognition commonly relies on antibodies. However, an alternative class of molecular recognition tools, aptamers, offers important advantages relative to antibodies(7,8). Aptamers are oligonucleotides generated by in-vitro selection: systematic evolution of ligands by exponential enrichment (SELEX)(9,10). SELEX is an iterative process that, similar to Darwinian evolution, allows selection, amplification, enrichment, and perpetuation of a property, e.g., avid, specific, ligand binding (aptamers) or catalytic activity (ribozymes and DNAzymes). Despite emergence of aptamers as tools in modern biotechnology and medicine(11), they have been underutilized in the amyloid field. Few RNA or ssDNA aptamers have been selected against various forms of prion proteins (PrP)(12-16). An RNA aptamer generated against recombinant bovine PrP was shown to recognize bovine PrP-beta(17), a soluble, oligomeric, beta-sheet-rich conformational variant of full-length PrP that forms amyloid fibrils(18). Aptamers generated using monomeric and several forms of fibrillar beta(2;)-microglobulin (beta(2;)m) were found to bind fibrils of certain other amyloidogenic proteins besides beta(2;)m fibrils(19). Ylera et al. described RNA aptamers selected against immobilized monomeric Abeta40(20). Unexpectedly, these aptamers bound fibrillar Abeta40. Altogether, these data raise several important questions. Why did aptamers selected against monomeric proteins recognize their polymeric forms? Could aptamers against monomeric and/or oligomeric forms of amyloidogenic proteins be obtained? To address these questions, we attempted to select aptamers for covalently-stabilized oligomeric Abeta40(21) generated using photo-induced cross-linking of unmodified proteins (PICUP)(22,23). Similar to previous findings(17,19,20), these aptamers reacted with fibrils of Abeta and several other amyloidogenic proteins likely recognizing a potentially common amyloid structural aptatope(21). Here, we present the SELEX methodology used in production of these aptamers(21).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616783      PMCID: PMC2918391          DOI: 10.3791/1955

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  28 in total

1.  Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins.

Authors:  G Bitan; A Lomakin; D B Teplow
Journal:  J Biol Chem       Date:  2001-07-05       Impact factor: 5.157

Review 2.  Clinical practice. Early Alzheimer's disease.

Authors:  Claudia H Kawas
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

3.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

4.  In vitro selection of RNA molecules that bind specific ligands.

Authors:  A D Ellington; J W Szostak
Journal:  Nature       Date:  1990-08-30       Impact factor: 49.962

5.  Prion-protein-specific aptamer reduces PrPSc formation.

Authors:  Daniela Proske; Sabine Gilch; Franziska Wopfner; Hermann M Schätzl; Ernst-L Winnacker; Michael Famulok
Journal:  Chembiochem       Date:  2002-08-02       Impact factor: 3.164

Review 6.  Advances in the early detection of Alzheimer's disease.

Authors:  Peter J Nestor; Philip Scheltens; John R Hodges
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

7.  Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.

Authors:  Chi-Hong B Chen; George A Chernis; Van Q Hoang; Ralf Landgraf
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-21       Impact factor: 11.205

Review 8.  Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies.

Authors:  Marina D Kirkitadze; Gal Bitan; David B Teplow
Journal:  J Neurosci Res       Date:  2002-09-01       Impact factor: 4.164

9.  RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity.

Authors:  Farid Rahimi; Kazuma Murakami; Jamie L Summers; Chi-Hong B Chen; Gal Bitan
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

10.  Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion.

Authors:  Alexandre Rhie; Louise Kirby; Natalie Sayer; Rosanna Wellesley; Petra Disterer; Ian Sylvester; Andrew Gill; James Hope; William James; Abdessamad Tahiri-Alaoui
Journal:  J Biol Chem       Date:  2003-08-05       Impact factor: 5.157

View more
  10 in total

1.  Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells.

Authors:  Lindsay Jones Talbot; Zhiyong Mi; Syamal Dave Bhattacharya; Victoria Kim; Hongtao Guo; Paul C Kuo
Journal:  Surgery       Date:  2011-08       Impact factor: 3.982

Review 2.  Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.

Authors:  Maryam Tabarzad; Marzieh Jafari
Journal:  Protein J       Date:  2016-04       Impact factor: 2.371

Review 3.  Aptamer and its applications in neurodegenerative diseases.

Authors:  Jing Qu; Shuqing Yu; Yuan Zheng; Yan Zheng; Hui Yang; Jianliang Zhang
Journal:  Cell Mol Life Sci       Date:  2016-08-25       Impact factor: 9.261

Review 4.  Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders.

Authors:  Islauddin Khan; Kumari Preeti; Valencia Fernandes; Dharmendra Kumar Khatri; Shashi Bala Singh
Journal:  Cell Mol Neurobiol       Date:  2021-05-01       Impact factor: 4.231

Review 5.  Aptamers as both drugs and drug-carriers.

Authors:  Md Ashrafuzzaman
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

Review 6.  Aptamers Selected for Recognizing Amyloid β-Protein-A Case for Cautious Optimism.

Authors:  Farid Rahimi
Journal:  Int J Mol Sci       Date:  2018-02-27       Impact factor: 5.923

7.  Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation.

Authors:  Yuan Zheng; Jing Qu; Fenqin Xue; Yan Zheng; Bo Yang; Yongchang Chang; Hui Yang; Jianliang Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2018-03-06       Impact factor: 8.886

Review 8.  Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease.

Authors:  Yan Zheng; Limin Zhang; Jinge Zhao; Lingyun Li; Minxuan Wang; Peifeng Gao; Qing Wang; Xiaoling Zhang; Weizhi Wang
Journal:  Theranostics       Date:  2022-01-31       Impact factor: 11.556

9.  Current progress of RNA aptamer-based therapeutics.

Authors:  Jiehua Zhou; Maggie L Bobbin; John C Burnett; John J Rossi
Journal:  Front Genet       Date:  2012-11-02       Impact factor: 4.599

Review 10.  Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids.

Authors:  Bruno Macedo; Yraima Cordeiro
Journal:  Int J Mol Sci       Date:  2017-05-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.